Medtronic, Inc. (MDT) Nets New Indications for Resolute Integrity Drug-Eluting Stent in Europe
5/16/2012 10:27:01 AM
PARIS--(BUSINESS WIRE)--As EuroPCR 2012 gets under way today, Medtronic, Inc. (NYSE: MDT) announced that the Resolute Integrity Coronary Stent System has received European regulatory approval for several new indications, making it the drug-eluting stent (DES) with the broadest range of approved indications in Europe.
|